Links to Exploration step
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers</title><author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name><affiliation><nlm:aff id="aff1"><institution>Department of Urology, Asklepios Hospital Barmbek</institution>, Hamburg 22291,<country>Germany</country></nlm:aff></affiliation></author><author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name><affiliation><nlm:aff id="aff1"><institution>Department of Urology, Asklepios Hospital Barmbek</institution>, Hamburg 22291,<country>Germany</country></nlm:aff></affiliation></author><author><name sortKey="Herrmann, Thomas Rw" sort="Herrmann, Thomas Rw" uniqKey="Herrmann T" first="Thomas Rw" last="Herrmann">Thomas Rw Herrmann</name><affiliation><nlm:aff id="aff2"><institution>Department of Urology, MHH Medical School of Hannover</institution>, Hannover 30625,<country>Germany</country></nlm:aff></affiliation></author><author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J" last="Gross">Andreas J. Gross</name><affiliation><nlm:aff id="aff1"><institution>Department of Urology, Asklepios Hospital Barmbek</institution>, Hamburg 22291,<country>Germany</country></nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">22231295</idno><idno type="pmc">3735080</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3735080</idno><idno type="RBID">PMC:3735080</idno><idno type="doi">10.1038/aja.2011.167</idno><date when="2012">2012</date><idno type="wicri:Area/Pmc/Corpus">000003</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000003</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers</title><author><name sortKey="Netsch, Christopher" sort="Netsch, Christopher" uniqKey="Netsch C" first="Christopher" last="Netsch">Christopher Netsch</name><affiliation><nlm:aff id="aff1"><institution>Department of Urology, Asklepios Hospital Barmbek</institution>, Hamburg 22291,<country>Germany</country></nlm:aff></affiliation></author><author><name sortKey="Bach, Thorsten" sort="Bach, Thorsten" uniqKey="Bach T" first="Thorsten" last="Bach">Thorsten Bach</name><affiliation><nlm:aff id="aff1"><institution>Department of Urology, Asklepios Hospital Barmbek</institution>, Hamburg 22291,<country>Germany</country></nlm:aff></affiliation></author><author><name sortKey="Herrmann, Thomas Rw" sort="Herrmann, Thomas Rw" uniqKey="Herrmann T" first="Thomas Rw" last="Herrmann">Thomas Rw Herrmann</name><affiliation><nlm:aff id="aff2"><institution>Department of Urology, MHH Medical School of Hannover</institution>, Hannover 30625,<country>Germany</country></nlm:aff></affiliation></author><author><name sortKey="Gross, Andreas J" sort="Gross, Andreas J" uniqKey="Gross A" first="Andreas J" last="Gross">Andreas J. Gross</name><affiliation><nlm:aff id="aff1"><institution>Department of Urology, Asklepios Hospital Barmbek</institution>, Hamburg 22291,<country>Germany</country></nlm:aff></affiliation></author></analytic><series><title level="j">Asian Journal of Andrology</title><idno type="ISSN">1008-682X</idno><idno type="eISSN">1745-7262</idno><imprint><date when="2012">2012</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>This study compared the efficacy of 70- and 120-w 2-µm thulium:YAG VapoEnucleation of the prostate (ThuVEP) for patients with benign prostatic obstruction (BPO). A prospective analysis of 84 patients with symptomatic BPO and prostatic enlargement (≥60 ml) who underwent either 70-w (<italic>n</italic>=44) or 120-w ThuVEP (<italic>n</italic>=40) non-randomly was carried out. Patient demographics and perioperative and 12-month follow-up data were analysed. The mean prostate volume was 79.90±27.49 ml in patients who had received 70-w ThuVEP, which was less than in those who had received 120-w ThuVEP (88.53±25.10; <italic>P</italic>=0.033). The mean enucleation (resected weight/laser time, 2.16±1.21 g min<sup>−1</sup><italic>vs.</italic> 1.23±0.60 g min<sup>−1</sup>; <italic>P</italic>=0.013), operation efficiency (resected weight/total operation time, 0.76±0.35 g min<sup>−1</sup><italic>vs.</italic> 0.42±0.27 g min<sup>−1</sup>; <italic>P</italic>=0.000) and percentage of resected tissue (66.93%±22.79% <italic>vs.</italic> 45.41%±23.33% <italic>P</italic>=0.000) were higher with 120-w treatment compared to 70-w ThuVEP. One patient (1.2% of total patients) (in the 120-w group) required a blood transfusion postoperatively. Sixty-one patients (73%) were available for review at the 12-month follow-up time point. The quality of life (QoL), International Prostate Symptom Score (IPSS), maximum urinary flow rate (<italic>Q</italic><sub>max</sub>), postvoiding residual urine (PVR) and prostate volume improved significantly after treatment (<italic>P</italic>≤0.035) and were not significantly different between those treated with the different devices (70- and 120-w). The median prostate volume reduction was 81.70% and 82.19% with 70- and 120-w ThuVEP, respectively. The incidence of complications was low and did not differ between groups treated with the different devices. Two patients (2.4%) (one per group) had a bladder neck contracture at the follow-up. ThuVEP is a safe and efficacious procedure for the treatment of symptomatic BPO. The incidence of complications was low with both devices. The 120-w thulium:YAG device enhances the effectiveness of ThuVEP with regard to the percentage of resected tissue and the enucleation/operation efficiency.</p></div></front></TEI><pmc article-type="research-article"><pmc-comment>The publisher of this article does not allow downloading of the full text in XML form.</pmc-comment>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Asian J Androl</journal-id><journal-id journal-id-type="iso-abbrev">Asian J. Androl</journal-id><journal-title-group><journal-title>Asian Journal of Andrology</journal-title></journal-title-group><issn pub-type="ppub">1008-682X</issn><issn pub-type="epub">1745-7262</issn><publisher><publisher-name>Nature Publishing Group</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">22231295</article-id><article-id pub-id-type="pmc">3735080</article-id><article-id pub-id-type="pii">aja2011167</article-id><article-id pub-id-type="doi">10.1038/aja.2011.167</article-id><article-categories><subj-group subj-group-type="heading"><subject>Original Article</subject></subj-group></article-categories><title-group><article-title>Thulium:YAG VapoEnucleation of the prostate in large glands: a prospective comparison using 70- and 120-W 2-µm lasers</article-title><alt-title alt-title-type="running">Seventy- and 120-w 2-µm Tm:YAG VapoEnucleation</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Netsch</surname><given-names>Christopher</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Bach</surname><given-names>Thorsten</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib contrib-type="author"><name><surname>Herrmann</surname><given-names>Thomas RW</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib contrib-type="author"><name><surname>Gross</surname><given-names>Andreas J</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><aff id="aff1"><label>1</label><institution>Department of Urology, Asklepios Hospital Barmbek</institution>, Hamburg 22291,<country>Germany</country></aff><aff id="aff2"><label>2</label><institution>Department of Urology, MHH Medical School of Hannover</institution>, Hannover 30625,<country>Germany</country></aff></contrib-group><author-notes><corresp id="caf1"><label>*</label>(<email>c.netsch@asklepios.com</email>)</corresp></author-notes><pub-date pub-type="ppub"><month>03</month><year>2012</year></pub-date><pub-date pub-type="epub"><day>09</day><month>01</month><year>2012</year></pub-date><volume>14</volume><issue>2</issue><fpage>325</fpage><lpage>329</lpage><history><date date-type="received"><day>09</day><month>08</month><year>2011</year></date><date date-type="rev-recd"><day>23</day><month>09</month><year>2011</year></date><date date-type="accepted"><day>19</day><month>10</month><year>2011</year></date></history><permissions><copyright-statement>Copyright © 2012 SIMM & SJTU</copyright-statement><copyright-year>2012</copyright-year><copyright-holder>SIMM & SJTU</copyright-holder></permissions><abstract><p>This study compared the efficacy of 70- and 120-w 2-µm thulium:YAG VapoEnucleation of the prostate (ThuVEP) for patients with benign prostatic obstruction (BPO). A prospective analysis of 84 patients with symptomatic BPO and prostatic enlargement (≥60 ml) who underwent either 70-w (<italic>n</italic>=44) or 120-w ThuVEP (<italic>n</italic>=40) non-randomly was carried out. Patient demographics and perioperative and 12-month follow-up data were analysed. The mean prostate volume was 79.90±27.49 ml in patients who had received 70-w ThuVEP, which was less than in those who had received 120-w ThuVEP (88.53±25.10; <italic>P</italic>=0.033). The mean enucleation (resected weight/laser time, 2.16±1.21 g min<sup>−1</sup><italic>vs.</italic> 1.23±0.60 g min<sup>−1</sup>; <italic>P</italic>=0.013), operation efficiency (resected weight/total operation time, 0.76±0.35 g min<sup>−1</sup><italic>vs.</italic> 0.42±0.27 g min<sup>−1</sup>; <italic>P</italic>=0.000) and percentage of resected tissue (66.93%±22.79% <italic>vs.</italic> 45.41%±23.33% <italic>P</italic>=0.000) were higher with 120-w treatment compared to 70-w ThuVEP. One patient (1.2% of total patients) (in the 120-w group) required a blood transfusion postoperatively. Sixty-one patients (73%) were available for review at the 12-month follow-up time point. The quality of life (QoL), International Prostate Symptom Score (IPSS), maximum urinary flow rate (<italic>Q</italic><sub>max</sub>), postvoiding residual urine (PVR) and prostate volume improved significantly after treatment (<italic>P</italic>≤0.035) and were not significantly different between those treated with the different devices (70- and 120-w). The median prostate volume reduction was 81.70% and 82.19% with 70- and 120-w ThuVEP, respectively. The incidence of complications was low and did not differ between groups treated with the different devices. Two patients (2.4%) (one per group) had a bladder neck contracture at the follow-up. ThuVEP is a safe and efficacious procedure for the treatment of symptomatic BPO. The incidence of complications was low with both devices. The 120-w thulium:YAG device enhances the effectiveness of ThuVEP with regard to the percentage of resected tissue and the enucleation/operation efficiency.</p></abstract><kwd-group><kwd>benign prostatic obstruction</kwd><kwd>laser</kwd><kwd>prostate</kwd><kwd>Revolix</kwd><kwd>Tm:YAG</kwd><kwd>ThuVEP</kwd><kwd>VapoEnucleation</kwd></kwd-group></article-meta></front></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Terre/explor/ThuliumV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 0000039 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 0000039 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Terre
|area= ThuliumV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé=
|texte=
}}
| This area was generated with Dilib version V0.6.21. |  |